CVRX (CVRX) Q2 2025: 35% New Sales Hires Drive Account Expansion, Reimbursement Tailwinds Build
CVRX’s Salesforce overhaul reached a pivotal phase as 35% of territory managers are new since January, fueling a 27% YoY increase in active implanting centers and underpinning double-digit revenue growth. Execution now shifts from hiring to onboarding and productivity, while reimbursement milestones and clinical evidence set the stage for broader Barostim adoption in 2026. Investors should focus on the ramp of new reps and the practical impact of Category 1 CPT code transition on commercial momentum.
Summary
- Salesforce Transformation: Aggressive hiring filled open roles, with over a third of territory managers new since January.
- Reimbursement Milestones: Category 1 CPT code and CMS payment updates remove key adoption barriers starting January 2026.
- Productivity Ramp Focus: Management pivots from hiring to onboarding and training to accelerate new rep productivity.
Performance Analysis
CVRX delivered 15% revenue growth, driven by continued U.S. heart failure business expansion and account additions. Active implanting centers in the U.S. rose to 240, up from 189 a year ago, demonstrating that the company’s account-based strategy is yielding tangible network effects. The U.S. contributed the vast majority of revenue, with Europe a small but growing component. Gross margin remained robust at 84%, steady with the prior year, despite an uptick in SG&A tied to salesforce investments.
Operating expenses climbed, primarily reflecting higher compensation, travel, and stock-based comp, while R&D spend declined as clinical trial design discussions with FDA progressed but have yet to scale. Net loss widened marginally, but cash burn was lower YoY, signaling some operating leverage. Notably, over 35% of sales territory managers are new hires, and more than half of area sales directors are within their first year, underscoring the scale of commercial transformation underway.
- Account Expansion Momentum: 13 net new implanting centers added in Q2, with high-single digit to low-double digit adds expected quarterly.
- SG&A Peak Passed: Q2 marked the seasonal high point for SG&A; management expects costs to moderate in H2.
- Cash Position Solid: $95 million in cash provides runway for ongoing commercial and clinical investment.
Execution in the second half hinges on how quickly the new sales cohort can reach full productivity, which will determine the pace of territory and revenue expansion into 2026.
Executive Commentary
"We are largely through the necessary transitions in the sales team that we initiated in Q4, and turnover is returning to normal. Importantly, we have aggressively hired since January to fill the open roles with strong talent. While we are enthusiastic about the team in the field, They are still early in their tenure, with more than 35% of territory managers hired since January 1."
Kevin Hikes, President and Chief Executive Officer
"With narrowing the top end to be $55 to $57 million, it really only moves the midpoint by about $500,000...it really just does come back to how quickly we're getting this new team up to speed and getting them productive. We continue to believe we have the right team and strategy in place. And now it's simply focusing on getting those reps up that productivity curve as quickly as possible."
Jared O'Shine, Chief Financial Officer
Strategic Positioning
1. Salesforce Overhaul and Productivity Ramp
CVRX’s commercial model relies on territory managers building sustainable Barostim programs, with a focus on both Tier 1/2 flagship and select Tier 3/4 satellite centers. The company has transitioned from a hiring-centric phase (35% of TMs new since January) to a training and productivity phase, investing in onboarding and playbook-driven account targeting. Early signs show that well-positioned new hires are starting to contribute, but the full productivity curve is expected to play out over six to twelve months per rep.
2. Account Segmentation and Expansion Strategy
Account segmentation, a data-driven approach to prioritize centers by potential, is evolving as CVRX finds success even in non-traditional (Tier 3/4) accounts with strong clinical and administrative champions. Satellite centers are increasingly leveraged as entry points to larger flagship institutions, refining the go-to-market playbook for broader network penetration.
3. Reimbursement Tailwinds and Policy Milestones
Reimbursement friction is set to drop sharply in 2026, as Barostim transitions to a Category 1 CPT code, eliminating automatic experimental denials and improving payment predictability. CMS’s assignment to New Technology APC 1580 and the pursuit of a Level 6 neurostimulator APC signal regulatory validation and financial support for outpatient procedures, while physician payment formalization (11 work RVUs) removes a longstanding barrier to adoption.
4. Clinical Evidence and Awareness Building
Progress with the FDA on a randomized controlled trial, along with continued real-world and investigator-sponsored data generation, aims to strengthen the evidence base for Barostim. Simultaneously, CVRX is scaling educational outreach, especially to advanced practice providers, to drive awareness and referral activity—over 100 APP-focused programs have been delivered YTD.
5. Operational Leadership and Infrastructure
The appointment of a new Chief Operating Officer, with deep medtech experience, signals a commitment to operational scale and quality as the company moves from commercial foundation-laying to execution at greater scale. This is a key step as Barostim pursues standard-of-care status in heart failure therapy.
Key Considerations
CVRX’s Q2 was defined by the balancing act between rapid commercial team scaling and the need for near-term productivity gains. The company’s strategic context is shaped by three adoption barriers—reimbursement, awareness, and evidence—each seeing incremental progress this quarter.
Key Considerations:
- Sales Rep Productivity Curve: The pace at which new territory managers ramp will dictate near-term revenue and territory expansion.
- Reimbursement Transition Impact: Category 1 CPT code adoption in January 2026 should materially reduce payer friction and improve physician economics.
- Account Segmentation Flexibility: Willingness to opportunistically pursue high-potential Tier 3/4 centers could accelerate penetration into flagship institutions.
- SG&A Leverage Watch: Management expects SG&A to normalize after Q2’s seasonal peak, but ongoing investment in training and clinical programs may keep costs elevated.
- Clinical Data as Commercial Lever: Progress on the randomized trial and real-world data could further support payer and physician adoption arguments.
Risks
Execution risk remains high as over one-third of the salesforce is new and productivity curves vary by rep background and territory quality. Reimbursement improvements are promising but not yet realized, and delays or complications in the CMS or CPT code transitions could slow adoption. Competitive therapies and physician inertia continue to present friction, while cash burn, though improved, will require ongoing vigilance as commercial and clinical investments scale.
Forward Outlook
For Q3 2025, CVRX guided to:
- Total revenue between $13.7 million and $14.7 million
For full-year 2025, management narrowed guidance:
- Total revenue of $55 million to $57 million
- Gross margin between 83% and 84%
- Operating expenses between $96 million and $98 million
Leadership emphasized that guidance hinges on the speed of new rep productivity ramp and that territory expansion should accelerate as onboarding completes. SG&A is expected to moderate in the second half. The reimbursement environment should improve further in 2026, setting up a potential inflection in commercial adoption.
Takeaways
CVRX is at a commercial inflection point as the focus shifts from hiring to productivity, with reimbursement and clinical milestones poised to unlock broader adoption in 2026 and beyond.
- Commercial Model in Transition: Execution risk is tied to onboarding and ramp of a new, less-tenured salesforce, which will determine the pace of account and revenue growth in the next two quarters.
- Reimbursement and Evidence Tailwinds: Category 1 CPT code and CMS payment milestones are set to materially reduce adoption friction, while clinical evidence generation is building a stronger foundation for physician uptake.
- 2026 Adoption Inflection Watch: Investors should monitor salesforce productivity, territory expansion, and practical reimbursement impacts as leading indicators of a step-change in Barostim adoption and revenue trajectory.
Conclusion
CVRX’s Q2 marked a decisive shift from salesforce restructuring to execution, with a large cohort of new reps now tasked with driving Barostim program expansion. With reimbursement and clinical evidence tailwinds building, the next two quarters will test the company’s ability to translate commercial investment into sustainable growth ahead of key 2026 milestones.
Industry Read-Through
CVRX’s experience highlights the critical interplay between salesforce scale-up, reimbursement milestones, and the adoption curve for novel medtech therapies. The transition from Category 3 to Category 1 CPT code status is a pivotal event that other device makers should watch closely, as it can transform payer dynamics and physician behavior. The emphasis on APP engagement and flexible account segmentation also signals a broader shift in go-to-market strategies for specialized cardiac devices, with implications for both large and small medtech players navigating reimbursement and evidence-driven adoption barriers.